West Pharmaceutical(US:WST)2025-10-23 12:00Financial Performance - Q3 2025 - Net sales reached $804.6 million, a 7.7% increase compared to Q3 2024, with organic growth of 5.0%[16, 17] - Adjusted diluted EPS was $1.96, a 5.9% increase compared to Q3 2024[16, 17] - Adjusted operating profit margin was 21.1%, a decrease of 40 bps compared to Q3 2024[16, 17] Segment Performance - Proprietary Products net sales were $647.5 million, a 7.7% increase year-over-year, with organic growth of 5.1%[22] - Contract Manufacturing net sales were $157.1 million, an 8.0% increase year-over-year, with organic growth of 4.9%[29, 31] Revenue Breakdown - Biologics accounted for 41% of total company revenue, with sales of $329.1 million, an 11.0% increase year-over-year[19, 36] - HVP Components accounted for 48% of total company revenue, with sales of $390.0 million, a 16.3% increase year-over-year[22, 34, 38] - Generics accounted for 17% of total company revenue, with sales of $135.9 million, a 4.0% increase year-over-year[34, 36] - Pharma accounted for 22% of total company revenue, with sales of $182.5 million, a 4.7% increase year-over-year[34, 36] Geographic Performance - Americas accounted for 47% of total company revenue, with sales of $375.3 million, a 5.3% increase year-over-year[34, 40] - Europe, Middle East, and Africa accounted for 45% of total company revenue, with sales of $361.1 million, a 9.4% increase year-over-year[34, 40] - Asia Pacific accounted for 8% of total company revenue, with sales of $68.2 million, a 13.1% increase year-over-year[34, 40] Guidance - The company projects revenue between $3.060 billion and $3.070 billion for the full year 2025[43]